Abstract: A switch circuit includes FETs including a first FET group including m FETs, a second FET group including n FETs at a position away from the input terminal than the first FET group, and an intermediate FET between the first FET group and the second FET group, and capacitive elements including m capacitive elements, n capacitive elements, and an intermediate capacitive element, the capacitive element (C1i) (i is an integer between 1 and m inclusive) is connected in parallel to i consecutive FETs of the first FET group starting from a top closer to the input terminal, the capacitive element (C2j) (j is an integer between 1 and n inclusive) is connected in parallel to j consecutive FETs of the second FET group starting from a top closer to the input terminal, and the intermediate capacitive element is connected in parallel to the intermediate FET.

Abstract: A switch circuit includes FETs including a first FET group including m FETs, a second FET group including n FETs at a position away from the input terminal than the first FET group, and an intermediate FET between the first FET group and the second FET group, and capacitive elements including m capacitive elements, n capacitive elements, and an intermediate capacitive element, the capacitive element (C1i) (i is an integer between 1 and m inclusive) is connected in parallel to i consecutive FETs of the first FET group starting from a top closer to the input terminal, the capacitive element (C2j) (j is an integer between 1 and n inclusive) is connected in parallel to j consecutive FETs of the second FET group starting from a top closer to the input terminal, and the intermediate capacitive element is connected in parallel to the intermediate FET.

Abstract: Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture.

Abstract: Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture.

Abstract: Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture.

Abstract: A switching circuit that includes a first transfer path and a second transfer path that transfer a high frequency signal, a first transistor that electrically cuts off a common node between the first transfer path and the second transfer path and the first transfer path if the high frequency signal is transferred via the second transfer path, a second transistor that electrically cuts off the common node and the second transfer path if the high frequency signal is transferred via the first transfer path, a first control voltage input terminal that inputs a high-level control voltage if the high frequency signal is transferred via one of the first transfer path and the second transfer path, and a first voltage supply path that supplies a voltage according to the high-level control voltage to the common node.

Abstract: The invention provides an agent for preventing or treating arthritis, a cartilage protecting agent, a joint destruction inhibitor and a synovial membrane growth inhibitor comprising an anti-FGF-8 neutralizing antibody as an active ingredient, as well as a diagnostic agent of arthritis comprising an anti-FGF-8 antibody as an active ingredient and a method for judging arthritis using the antibody.

Abstract: An antiobesity agent, an antidiabetic agent, and/or a hypolipidemic agent comprising an angiopoietin-related growth factor (AGF) or a polynucleotide encoding the same as an active ingredient a polypeptide are disclosed. Further, a functional food or a health food for alleviating obesity, diabetes, and/or hyperlipemia, comprising the AGF as an active ingredient is disclosed. Furthermore, a method for treating or preventing obesity, diabetes, and/or hyperlipemia, comprising administering to a subject the AGF or a polynucleotide encoding the same is disclosed. Furthermore, use of the AGF or a polynucleotide encoding the same in the manufacture of an antiobesity agent, an antidiabetic agent, and/or a hypolipidemic agent is disclosed.

Abstract: Subjects of the present invention are to establish a technology for separating, isolating and culturing a stem cell derived from adult tissue while retaining the in vivo properties thereof, and to provide a preventive and/or therapeutic agent for diseases which accompany tissue injury, which comprises a stem cell derived from adult tissue as an active ingredient. In order to solve the subjects, the present invention provides a stem cell derived from adult tissue which is CD45-negative and CXCR4-positive. Also, the present invention provides a preventive and/or therapeutic agent for diseases which accompany tissue injury, which comprises the stem cell as an active ingredient.

Abstract: The invention provides an agent for preventing or treating arthritis, a cartilage protecting agent, a joint destruction inhibitor and a synovial membrane growth inhibitor comprising an anti-FGF-8 neutralizing antibody as an active ingredient, as well as a diagnostic agent of arthritis comprising an anti-FGF-8 antibody as an active ingredient and a method for judging arthritis using the antibody.

Abstract: A switching device for switching a plurality of RF signal lines to deliver a selected one of the RF signals to a receiver has an isolation D/U characteristic as high as 40 dB or higher. The switching device includes a mounting board made of dielectric and a matrix switch mounted thereon and implemented by one or more of SWIC. The RF signal lines in the switching device has no crossing point therebetween on either side of the mounting board to achieve the high isolation D/U ratio or lower cross-talk.

Abstract: The present invention relates to an agent for preventing or treating arthritis which comprises as an active ingredient a plant belonging to the family Saxifragaceae or its extract, foods and drinks or feeds comprising a plant belonging to the family Saxifragaceae or its extract, a method for preventing or treating arthritis in animals which comprises giving animals an agent or a feed for preventing or treating arthritis, and a food and drink or feed for preventing or treating arthritis which comprises as an active ingredient a plant belonging to the family Saxifragaceae or its extract.

Abstract: A switching device for switching a plurality of RF signal lines to deliver a selected one of the RF signals to a receiver has an isolation D/U characteristic as high as 40 dB or higher. The switching device includes a mounting board made of dielectric and a matrix switch mounted thereon and implemented by one or more of SWIC. The RF signal lines in the switching device has no crossing point therebetween on either side of the mounting board to achieve the high isolation D/U ratio or lower cross-talk.

Abstract: A method of producing monoclonal antibodies that bind to tumor-associated gangliosides, the method comprising: (1) immunizing a host with tumor cells; (2) boosting the host with a suspension comprising a mixture of tumor cell membrane and at least one purified lactonized tumor-associated ganglioside; (3) boosting the host with an immunogen comprising a lactone of a tumor associated ganglioside adsorbed on or incorporated into a carrier; (4) fusing immunized cells from the host with myeloma cells to form hybridoma cells; (5) selecting hybridoma cells that produce antibody that binds to the ganglioside of step (3); (6) culturing the selected hybridoma cells; and (7) recovering the antibody.